Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.


To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma. (MesoTRAP)

Primary Outcome Measures To measure the standard deviation of Visual Analogue Scale scores for breathlessness [ Time Frame: Daily from randomisation to 12 months ] The Visual Analogue Scale (VAS) is a 100mm line for patients to record the severity of a their breathlessness where 0mm is "No breathlessness at all" and ... [More >>]

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

Primary Outcome Measures Overall response rate [ Time Frame: 3 years ] defined by modified RECIST 1.1 for mesothelioma Eligibility Inclusion Criteria Patient willing and able to provide written informed consent for the trial. Patient age ≥ 18 at time of consent. Histologically or cytologically confirmed malignant pleural or peritoneal mesothelioma (MPM). No plans for surgical resection. PD-L1 expression ... [More >>]

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Primary Outcome Measures Progression-free survival of the participants(PFS) [ Time Frame: 24 months ] From starting date of anti-PD-1 antibody treatment until date of until the date of first documented disease progression or date of death from any cause, whichever comes first. Secondary Outcome Measures Overall survival of the participants(OS) [ Time Frame: 24 ... [More >>]

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Primary Outcome Measures Phase I part: Incidence of dose limiting toxicities (DLTs) [ Time Frame: 30 months ] A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications ... [More >>]

A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

Primary Outcome Measures Number of patients with any (Serious and Non-Serious) Adverse Event measured to assess safety and tolerability [ Time Frame: 6 months ] Secondary Outcome Measures To determine and compare tumour-specific immunological activation in the peripheral blood in the experimental group and the control group. Number of patients in the respective ... [More >>]

Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers

Primary Outcome Measures Dose Limiting Toxicity [ Time Frame: Up to 4 weeks ] Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (or most current version) [ Time Frame: Screening through 4 weeks after study completion, an average ... [More >>]

Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders

Primary Outcome Measures Signal to Noise Ratio [ Time Frame: 2 years ] The primary objective of this study is to determine an optimized set of scan parameters that will produce clear, anatomically and clinically relevant images of the lungs for healthy participants and various types of lung disorder participants, and using ... [More >>]

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Primary Outcome Measures number of patients who have a clinical benefit rate (CBR) (cohort 1) [ Time Frame: at 18 weeks post initiation of treatment ]The CBR is defined as the proportion of patients CR, PR or SD at 18 weeks based on RECIST criteria. maximum tolerated dose (MTD) (cohort 2) [ ... [More >>]

Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma

Primary Outcome Measures CD 74 and VEGF detection effect on response to treatment [ Time Frame: Essay done before starting treatment and correlated with the response ] The paraffin blocks of the patients will be tested for CD74 and VEGF before starting treatment using IHC and the results will be correlated with ... [More >>]

Confocal Laser Endomicroscopy in Pleural Malignancies

Primary Outcome Measures Technical feasibility: Number of successful procedures with evaluable CLE-imaging [ Time Frame: cross sectional (1 day) ] Number of successful procedures with evaluable CLE-imaging Procedure-related adverse events [ Time Frame: cross sectional (1 day) ] Number of study-related adverse events To describe and develop visual descriptive image criteria (number of ... [More >>]

Last update: January 19, 2018. 04:57:31 pm.